Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CapForce Inc.OPGN · Entity 9776 | Chief Financial Officer | May 17, 2021 | May 19, 2021 |
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Senior Vice-President & CFO | August 12, 2026 | August 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CapForce Inc.
Report date May 17, 2021 · Filed May 19, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,509 |
Reported balance
After 2021-05-17 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2021-05-17 · Exercise / conversion · Acquired 583 · Balance 1,509 F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 584 |
Reported balance
After 2021-05-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-05-17 · Exercise / conversion · Disposed 583 · Balance 584 F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. F2: Represents vesting of restricted stock units ("RSUs") granted in May 2019 that convert into common stock on a one-for-one basis. F3: On May 17, 2019, the Reporting Person was granted 1,750 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant. |
Filing footnotes · ownership attribution and instrument terms
F1: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019.
F2: Represents vesting of restricted stock units ("RSUs") granted in May 2019 that convert into common stock on a one-for-one basis.
F3: On May 17, 2019, the Reporting Person was granted 1,750 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant.
SUPERNUS PHARMACEUTICALS, INC.
Report date August 12, 2026 · Filed August 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,733 |
Reported balance
After 2026-08-12 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-08-12 · Exercise / conversion · Acquired 1,250 · Balance 9,733 F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. |
| Common StockSEC Table I · non-derivative | Direct | 9,129 |
Reported balance
After 2026-08-12 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-08-12 · Tax withholding · Disposed 604 · Balance 9,129 F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units. |
| Performance Share UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2026-08-12 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-08-12 · Exercise / conversion · Disposed 1,250 · Balance 0 F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Includes an aggregate of 251 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan.
F2: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the vesting of Performance Share Units.
F3: On February 19, 2025, the Reporting Person was awarded Performance Share Units, a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on May 3, 2025.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2024 Filed Feb 26, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Unit · Derivative | 12,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027567 · tm247055-3_4seq1.xml · derivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. F4 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2025. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Unit · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027567 · tm247055-3_4seq1.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,000 Underlying: Common Stock · 500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. F3 · derivative.expiration_date: These restricted stock units are settled in common stock upon vesting, which occurs in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-027567 · tm247055-3_4seq1.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,004 F1 · balance_after: Includes an aggregate of 415 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| October 13, 2023 Filed Oct 13, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 4,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-109142 · tm2328365-1_4seq1.xml · derivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 23, 2023. F3 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F3 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document |
| October 13, 2023 Filed Oct 13, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 1,911 | $26.91 | $51,425.01 |
DisclosureSEC source: 0001104659-23-109142 · tm2328365-1_4seq1.xml · nonDerivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,089 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the PSU vesting. Read SEC document |
| October 13, 2023 Filed Oct 13, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 4,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-109142 · tm2328365-1_4seq1.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on February 23, 2023. Read SEC document |
| October 04, 2023 Filed Oct 6, 2023 21:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 4,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-107539 · tm2327888-1_4seq1.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,000 Underlying: Common Stock · 4,000 shares Expires not disclosed F2 · derivative.exercise_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. F2 · derivative.expiration_date: On February 23, 2023, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period, which objectives were established on June 12, 2023. Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Units · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-059842 · tm2315575-3_4seq1.xml · derivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting person on May 3, 2022. F3 · derivative.exercise_date: On May 3, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. F3 · derivative.expiration_date: On May 3, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 709 | $36.47 | $25,857.23 |
DisclosureSEC source: 0001104659-23-059842 · tm2315575-3_4seq1.xml · nonDerivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,650 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the PSU vesting. Read SEC document |
| May 11, 2023 Filed May 12, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-059842 · tm2315575-3_4seq1.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting person on May 3, 2022. Read SEC document |
| May 04, 2023 Filed May 8, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Units · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-057226 · tm2314899-2_4seq1.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed F1 · derivative.exercise_date: On May 3, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. F1 · derivative.expiration_date: On May 3, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| March 14, 2023 Filed Apr 10, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionPerformance Share Unit · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-043635 · tm2311944d2_4seq1.xml · derivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on May 3, 2022. F3 · derivative.exercise_date: On May 3, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. F3 · derivative.expiration_date: On May 3, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| March 14, 2023 Filed Apr 10, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 789 | $38.65 | $30,494.85 |
DisclosureSEC source: 0001104659-23-043635 · tm2311944d2_4seq1.xml · nonDerivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,052 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the PSU vesting. Read SEC document |
| March 14, 2023 Filed Apr 10, 2023 21:00 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Exercise / conversionCommon Stock | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-043635 · tm2311944d2_4seq1.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,841 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Shares of common stock received upon the settlement of certain performance share units granted to the Reporting Person on May 3, 2022. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-026086 · tm237737-19_4seq1.xml · derivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 23, 2024. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 23, 2024. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-23-026086 · tm237737-19_4seq1.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 23, 2024. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025371 · tm237737-9_4seq1.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 22:03 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-025371 · tm237737-9_4seq1.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,341 F1 · balance_after: Includes an aggregate of 841 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 22, 2023 Filed Apr 12, 2023 21:01 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Disposition to issuerRestricted Stock Units · Derivative | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-044666 · tm2312277-4_4aseq1.xml · derivative · entry 3 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F4 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. F4 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023. Read SEC document |
| February 22, 2023 Filed Apr 12, 2023 21:01 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | Tax withholdingCommon Stock | 193 | $38.57 | $7,444.01 |
DisclosureSEC source: 0001104659-23-044666 · tm2312277-4_4aseq1.xml · nonDerivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,148 F2 · shares: Represents the number of shares of common stock withheld by the Company to satisfy tax withholding requirements in connection with the RSU vesting. Read SEC document |
| February 22, 2023 Filed Apr 12, 2023 21:01 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantCommon Stock | 500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-044666 · tm2312277-4_4aseq1.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,341 F1 · balance_after: Includes an aggregate of 841 shares acquired by the Reporting Person through the Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 16, 2023 Filed Feb 21, 2023 22:02 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantPerformance Share Unit · Derivative | 1,500 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-023836 · tm237193-5_4seq1.xml · derivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires 2023-04-01 F1 · derivative.exercise_date: On May 3, 2022, the Reporting Person was awarded Performance Share Units a portion of which vested upon the achievement of individual performance objectives within a defined performance period. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:25 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-026879 · tm227622-5_4seq1.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. F3 · derivative.expiration_date: These restricted stock units will be settled in common stock upon vesting, such vesting to occur on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 02:25 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001104659-22-026879 · tm227622-5_4seq1.xml · derivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 22:14 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantRestricted Stock Units · Derivative | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-027391 · tm227764-1_4aseq1.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000 Underlying: Common Stock · 2,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents the right to receive one share of Supernus common stock upon vesting. F3 · derivative.exercise_date: The Reporting Person is amending Form 4 filed on February 24, 2022 to reflect that these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023, rather than such vesting occurring entirely on February 22, 2023. F3 · derivative.expiration_date: The Reporting Person is amending Form 4 filed on February 24, 2022 to reflect that these restricted stock units will be settled in common stock upon vesting, which will occur in four equal annual installments, beginning on February 22, 2023, rather than such vesting occurring entirely on February 22, 2023. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 22:14 UTC Amendment | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001104659-22-027391 · tm227764-1_4aseq1.xml · derivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on February 22, 2023. Read SEC document |
| August 23, 2021 Filed Aug 24, 2021 21:17 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantEmployee Stock Option (Right to Buy) · Derivative | 85,000 | $0.00 Strike: $25.09 | $0.00 |
DisclosureSEC source: 0001104659-21-109013 · tm2125812-2_4seq1.xml · derivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Senior Vice-President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock · 85,000 shares Expires 2031-08-23 F1 · derivative.exercise_date: The option vests in four equal annual installments beginning on August 23, 2021. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:45 UTC | CapForce Inc. OPGN · Entity 9776 | Exercise / conversionRestricted Stock Units · Derivative | 583 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-21-000398 · ownership.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 584 Underlying: Common Stock · 583 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. F2 · derivative.exercise_price: Represents vesting of restricted stock units ("RSUs") granted in May 2019 that convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On May 17, 2019, the Reporting Person was granted 1,750 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant. F3 · derivative.expiration_date: On May 17, 2019, the Reporting Person was granted 1,750 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant. Read SEC document |
| May 17, 2021 Filed May 19, 2021 20:45 UTC | CapForce Inc. OPGN · Entity 9776 | Exercise / conversionCommon Stock | 583 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-21-000398 · ownership.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 21:29 UTC | CapForce Inc. OPGN · Entity 9776 | GrantRestricted Stock Award · Derivative | 42,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-21-000154 · ownership.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of OpGen common stock. F4 · derivative.exercise_date: RSUs granted on March 3, 2021 pursuant to the OpGen 2015 Equity Incentive Plan. The RSUs have a two year vesting schedule, vesting annually in installments beginning March 3, 2022. F4 · derivative.expiration_date: RSUs granted on March 3, 2021 pursuant to the OpGen 2015 Equity Incentive Plan. The RSUs have a two year vesting schedule, vesting annually in installments beginning March 3, 2022. Read SEC document |
| March 03, 2021 Filed Mar 5, 2021 21:29 UTC | CapForce Inc. OPGN · Entity 9776 | GrantStock Option Award · Derivative | 42,500 | $0.00 Strike: $1.91 | $0.00 |
DisclosureSEC source: 0001079973-21-000154 · ownership.xml · derivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,500 Underlying: Common Stock · 42,500 shares Expires 2031-03-03 F1 · derivative.exercise_price: The exercise price is based on the closing price for shares of OpGen common stock on the date of grant. F2 · derivative.exercise_date: Stock option granted under the terms and provisions of the OpGen 2015 Equity Incentive Plan. The stock option vests in two equal annual installments beginning on March 3, 2022. Read SEC document |
| September 30, 2020 Filed Oct 2, 2020 21:36 UTC | CapForce Inc. OPGN · Entity 9776 | GrantStock Option Award · Derivative | 210,000 | $0.00 Strike: $2.12 | $0.00 |
DisclosureSEC source: 0001079973-20-000839 · ownership.xml · derivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 210,000 Underlying: Common Stock · 210,000 shares Expires 2030-09-30 F1 · derivative.exercise_date: The grant of stock options have a four year vesting schedule, vesting 25% on the first anniversary of the date of grant and the remaining options vesting 6.25% on the quarterly anniversary of the first vesting date for a period of three years, as long as the Reporting Person continues providing services to the Company on each such vesting date. Read SEC document |
| May 17, 2020 Filed May 20, 2020 00:36 UTC | CapForce Inc. OPGN · Entity 9776 | Exercise / conversionRestricted Stock Unit · Derivative | 583 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-20-000437 · ownership.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,167 Underlying: Common Stock · 583 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. F2 · derivative.exercise_price: Represents vesting of restricted stock units ("RSUs") granted in May 2019 that convert into common stock on a one-for-one basis. F3 · derivative.exercise_date: On May 17, 2019, the Reporting Person was granted 1,750 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant. F3 · derivative.expiration_date: On May 17, 2019, the Reporting Person was granted 1,750 RSUs (on a post-stock split basis). The RSUs were granted subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant. Read SEC document |
| May 17, 2020 Filed May 20, 2020 00:36 UTC | CapForce Inc. OPGN · Entity 9776 | Exercise / conversionCommon Stock | 583 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-20-000437 · ownership.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 926 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: All stock information is adjusted to reflect a twenty-five-to-one reverse stock split effected on August 29, 2019. Read SEC document |
| November 10, 2019 Filed Nov 12, 2019 23:33 UTC | CapForce Inc. OPGN · Entity 9776 | Exercise / conversionRestricted Stock Option · Derivative | 12 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001079973-19-000581 · ownership.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Cheif Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: Not disclosed Underlying: Common Stock · 12 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On November 10, 2019, one-fourth of a restricted stock unit award granted on November 10, 2015 vested and was earned. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments from the date of grant, with acceleration of vesting in certain circumstances associated with a change of control. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments from the date of grant, with acceleration of vesting in certain circumstances associated with a change of control. Read SEC document |
| November 10, 2019 Filed Nov 12, 2019 23:33 UTC | CapForce Inc. OPGN · Entity 9776 | Exercise / conversionCommon Stock | 12 | $0.00 | $0.00 |
DisclosureSEC source: 0001079973-19-000581 · ownership.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Cheif Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 345 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On November 10, 2019, one-fourth of a restricted stock unit award granted on November 10, 2015 vested and was earned. Read SEC document |
| May 17, 2019 Filed May 20, 2019 21:32 UTC | CapForce Inc. OPGN · Entity 9776 | GrantRestricted Stock Units · Derivative | 35,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001079973-19-000319 · ownership.xml · derivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents the right to acquire one share of Common Stock F2 · derivative.exercise_date: The restricted stock units are subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant. F2 · derivative.expiration_date: The restricted stock units are subject to forfeiture, which forfeiture restrictions will lapse as to one-third of the award on the first, second and third anniversaries of the date of grant, subject to acceleration as set forth in the Reporting Person's employment agreement with the Registrant. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 22:19 UTC | CapForce Inc. OPGN · Entity 9776 | Exercise / conversionRestricted Stock Units · Derivative | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-010542 · doc1.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: All stock information is adjusted to reflect a one-for-twenty-five reverse stock split effected on January 17, 2018. F2 · derivative.exercise_price: Each restricted stock unit represents the right to acquire one share of common stock. F3 · derivative.exercise_date: Represents lapse of forfeiture of restricted stock units granted in August 2017 upon achievement of a milestone event. F3 · derivative.expiration_date: Represents lapse of forfeiture of restricted stock units granted in August 2017 upon achievement of a milestone event. Read SEC document |
| February 23, 2018 Filed Feb 27, 2018 22:19 UTC | CapForce Inc. OPGN · Entity 9776 | Exercise / conversionCommon Stock | 1,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-18-010542 · doc1.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,408 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: All stock information is adjusted to reflect a one-for-twenty-five reverse stock split effected on January 17, 2018. Read SEC document |
| January 23, 2018 Filed Jan 25, 2018 21:59 UTC | CapForce Inc. OPGN · Entity 9776 | GrantStock Option Award · Derivative | 12,000 | $0.00 Strike: $4.02 | $0.00 |
DisclosureSEC source: 0001140361-18-003235 · doc1.xml · derivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2028-01-23 F1 · derivative.exercise_date: The options vest 25% on January 23, 2019 and 6.25% on the quarterly anniversary of the first vesting date for a period of three years. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 21:43 UTC | CapForce Inc. OPGN · Entity 9776 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-042839 · doc1.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On November 10, 2017, one-fourth of a restricted stock unit award granted on November 10, 2015 vested and was earned. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments from the date of grant, with acceleration of vesting in certain circumstances associated with a change of control. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments from the date of grant, with acceleration of vesting in certain circumstances associated with a change of control. Read SEC document |
| November 10, 2017 Filed Nov 14, 2017 21:43 UTC | CapForce Inc. OPGN · Entity 9776 | Exercise / conversionCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-042839 · doc1.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,216 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On November 10, 2017, one-fourth of a restricted stock unit award granted on November 10, 2015 vested and was earned. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 20:22 UTC | CapForce Inc. OPGN · Entity 9776 | GrantRestricted Stock Units · Derivative | 35,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-031408 · doc1.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a right to receive one share of OpGen, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest upon the successful launch of OpGen, Inc.'s cUTI RUO mAST. F2 · derivative.expiration_date: The restricted stock units vest upon the successful launch of OpGen, Inc.'s cUTI RUO mAST. Read SEC document |
| August 09, 2017 Filed Aug 11, 2017 20:22 UTC | CapForce Inc. OPGN · Entity 9776 | GrantStock Option Award · Derivative | 60,000 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001140361-17-031408 · doc1.xml · derivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2027-08-09 Read SEC document |
| July 18, 2017 Filed Jul 18, 2017 20:10 UTC | CapForce Inc. OPGN · Entity 9776 | GrantWarrants to purchase Common Stock · Derivative | 65,000 | $0.00 Strike: $0.43 | $0.00 |
DisclosureSEC source: 0001140361-17-028091 · doc1.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2022-07-18 Read SEC document |
| July 18, 2017 Filed Jul 18, 2017 20:10 UTC | CapForce Inc. OPGN · Entity 9776 | PurchaseCommon Stock | 65,000 | $0.40 | $26,000.00 |
DisclosureSEC source: 0001140361-17-028091 · doc1.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 118,966 Read SEC document |
| February 23, 2017 Filed Feb 27, 2017 22:12 UTC | CapForce Inc. OPGN · Entity 9776 | GrantStock Option Award · Derivative | 68,000 | $0.00 Strike: $1.03 | $0.00 |
DisclosureSEC source: 0001140361-17-009452 · doc1.xml · derivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,000 Underlying: Common Stock · 68,000 shares Expires 2027-02-23 F1 · derivative.exercise_date: The option vests 25% on February 23, 2018 and 6.25% quarterly thereafter on the first business day of each quarter for a period of three years. Read SEC document |
| November 10, 2016 Filed Feb 10, 2017 20:42 UTC | CapForce Inc. OPGN · Entity 9776 | Exercise / conversionRestricted Stock Units · Derivative | 6,250 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-005767 · doc1.xml · derivative · entry 2 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Stock · 6,250 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On November 10, 2016, one-fourth of a restricted stock unit award granted on November 10, 2015 vested and was earned, but the transaction was not reported on a timely basis. F2 · derivative.exercise_date: The restricted stock units vest in four equal annual installments from the date of grant with the first installment having vested on November 10, 2016, with acceleration of vesting in certain circumstances associated with a change of control. F2 · derivative.expiration_date: The restricted stock units vest in four equal annual installments from the date of grant with the first installment having vested on November 10, 2016, with acceleration of vesting in certain circumstances associated with a change of control. Read SEC document |
| November 10, 2016 Filed Feb 10, 2017 20:42 UTC | CapForce Inc. OPGN · Entity 9776 | Exercise / conversionCommon Stock | 6,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001140361-17-005767 · doc1.xml · nonDerivative · entry 1 DEC TIMOTHY C · CIK 0001194020 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: On November 10, 2016, one-fourth of a restricted stock unit award granted on November 10, 2015 vested and was earned, but the transaction was not reported on a timely basis. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.